Entasis Drug Patent Portfolio
Entasis owns 2 orange book drugs protected by 10 US patents Given below is the list of Entasis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376499 | Combination therapy for treatment of resistant bacterial infections | 17 Nov, 2035 | Active |
| US9968593 | Combination therapy for treatment of resistant bacterial infections | 17 Nov, 2035 | Active |
| US8889671 | Compounds And Methods For Treating Bacterial Infections | 21 Jan, 2034 | Active |
| US9187495 | Compounds And Methods For Treating Bacterial Infections | 21 Jan, 2034 | Active |
| US9540394 | Compounds And Methods For Treating Bacterial Infections | 21 Jan, 2034 | Active |
| US9839641 | Compounds And Methods For Treating Bacterial Infections | 21 Jan, 2034 | Active |
| US9309245 | Beta-lactamase inhibitor compounds | 02 Apr, 2033 | Active |
| US9623014 | β-lactamase inhibitor compounds | 02 Apr, 2033 | Active |
| US8658641 | Fused, Spirocyclic Heteroaromatic Compounds For The Treatment Of Bacterial Infections | 20 Jun, 2030 | Active |
| US9040528 | Chemical Compounds 542 | 13 Oct, 2029 | Active |
Latest Legal Activities on Entasis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Entasis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 26 Apr, 2024 | US9309245 |
| Notice of Final Determination- Ineligible | 26 Apr, 2024 | US10376499 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US9309245 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10376499 |
| Initial letter Re: PTE Application to regulating agency | 17 Jan, 2024 | US10376499 |
| Initial letter Re: PTE Application to regulating agency | 17 Jan, 2024 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 17 Nov, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 17 Nov, 2023 | US10376499 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Oct, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 09 Aug, 2023 | US10376499 |
| Requirement for information sent under 37 CFR 1.750 | 09 Aug, 2023 | US9309245 |
| Patent Term Extension Application under 35 USC 156 Filed | 24 Jul, 2023 | US10376499 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Feb, 2023 | US10376499 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2021 | US9968593 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Oct, 2020 | US9623014 |
Entasis's Family Patents
Entasis Drug List
Given below is the complete list of Entasis's drugs and the patents protecting them.
1. Nuzolvence
Nuzolvence is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8889671 | Compounds And Methods For Treating Bacterial Infections |
21 Jan, 2034
(7 years from now)
| Active |
| US9187495 | Compounds And Methods For Treating Bacterial Infections |
21 Jan, 2034
(7 years from now)
| Active |
| US9540394 | Compounds And Methods For Treating Bacterial Infections |
21 Jan, 2034
(7 years from now)
| Active |
| US9839641 | Compounds And Methods For Treating Bacterial Infections |
21 Jan, 2034
(7 years from now)
| Active |
| US8658641 | Fused, Spirocyclic Heteroaromatic Compounds For The Treatment Of Bacterial Infections |
20 Jun, 2030
(4 years from now)
| Active |
| US9040528 | Chemical Compounds 542 |
13 Oct, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuzolvence's drug page
2. Xacduro (copackaged)
Xacduro (copackaged) is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376499 | Combination therapy for treatment of resistant bacterial infections |
17 Nov, 2035
(9 years from now)
| Active |
| US9968593 | Combination therapy for treatment of resistant bacterial infections |
17 Nov, 2035
(9 years from now)
| Active |
| US9309245 | Beta-lactamase inhibitor compounds |
02 Apr, 2033
(7 years from now)
| Active |
| US9623014 | β-lactamase inhibitor compounds |
02 Apr, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xacduro (copackaged)'s drug page